Mubadala Health, G42 Healthcare partner to create integrated entity

UAE-based G42 Healthcare, and Mubadala Health have partnered to create an integrated healthcare company.

The new entity will leverage the strength of this combined network, which includes state-of-the-art healthcare facilities and digital platforms.

Hasan Jasem Al Nowais has been appointed CEO of the new entity and will also continue to lead Mubadala Health.

Peng Xiao, Group CEO of G42, stated: “We aim to build on the respective strengths of G42 Healthcare and Mubadala Health to unlock healthcare super-intelligence and facilitate global healthcare expansion. Our capabilities and experience in leveraging data and artificial intelligence will allow us to continue transforming the traditional healthcare ecosystem to deliver top-notch patient care, fueled by the latest breakthrough research – all in world-class facilities.”

Waleed Al Mokarrab Al Muhairi, chairman of Mubadala Health and deputy CEO of Mubadala, said: “The future of healthcare lies in the incredible, fast-moving advances being made in technology.  For over a decade, Mubadala has invested in the highest standard of patient care for the residents of the UAE across a number of specialties. We now seek to take patient care to the next level, into a new era of precision and personalized medicine.”

Mubadala Health and G42 Healthcare have joined forces to create a first-of-its-kind, integrated healthcare company that will enhance the regional healthcare landscape and deliver a new approach to personalised, patient-centric care. pic.twitter.com/P8I9OYK0cj

— مكتب أبوظبي الإعلامي (@admediaoffice) October 6, 2022

Hasan Jasem Al Nowais, CEO of Mubadala Health and the new entity, said: “The new company represents a truly integrated healthcare ecosystem where research, technology, AI, and genomics are combined with world-class care to optimise clinical outcomes. We are committed to ensuring that our exceptional team of physicians and caregivers have access to pioneering medical technologies and deliver unparalleled care to patients.”

The new company will explore international expansion and new partnerships, and focus on collaborating with with leading researchers and pharmaceutical and health tech ecosystems.

Across the two organisations, healthcare assets include Imperial College London Diabetes Centre, HealthPoint, National Reference Laboratory, HealthPlus, Danat Al Emarat, Moorfields Eye Hospital Abu Dhabi, Biogenix, the UAE’s Omics Center of Excellence, and Insights Research Organization & Solutions (IROS), the first UAE-based contract research organisation specialising in healthcare research.